Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Expanding Role of Data Science and Bioinformatics in Drug Discovery and Development.

Fingert HJ.

Clin Pharmacol Ther. 2018 Jan;103(1):47-49. doi: 10.1002/cpt.912. Epub 2017 Nov 14.

PMID:
29134636
2.

Assessing proarrhythmic potential of drugs when optimal studies are infeasible.

Rock EP, Finkle J, Fingert HJ, Booth BP, Garnett CE, Grant S, Justice RL, Kovacs RJ, Kowey PR, Rodriguez I, Sanhai WR, Strnadova C, Targum SL, Tsong Y, Uhl K, Stockbridge N.

Am Heart J. 2009 May;157(5):827-36, 836.e1. doi: 10.1016/j.ahj.2009.02.020. Review.

PMID:
19376308
3.

Brain natriuretic peptide: potential adjunct for cardiac risk assessment and management during treatment with experimental anticancer agents.

Varterasian ML, Meyer MB, Pressler ML, Fingert HJ, LoRusso PM.

AAPS J. 2007;9(2):E115-6. doi: 10.1208/aapsj0902012. No abstract available.

4.

Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development.

Curigliano G, Spitaleri G, Fingert HJ, de Braud F, Sessa C, Loh E, Cipolla C, De Pas T, Goldhirsch A, Shah R.

Eur J Cancer. 2008 Mar;44(4):494-500. Epub 2007 Nov 19. Review.

PMID:
18024014
5.

Cardiac safety, risk management, and oncology drug development.

Fingert HJ, Varterasian ML.

Clin Cancer Res. 2006 Jun 15;12(12):3646-7. No abstract available.

6.

Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961).

Panosyan EH, Grigoryan RS, Avramis IA, Seibel NL, Gaynon PS, Siegel SE, Fingert HJ, Avramis VI.

Anticancer Res. 2004 Mar-Apr;24(2C):1121-5.

7.

Performance characteristics of a multimedia system for clinical data management.

Fingert HJ, Schneider DR.

Cancer Pract. 1994 May-Jun;2(3):194-201.

PMID:
8055023
8.

Cyclin E, a potential prognostic marker for breast cancer.

Keyomarsi K, O'Leary N, Molnar G, Lees E, Fingert HJ, Pardee AB.

Cancer Res. 1994 Jan 15;54(2):380-5.

9.

The fluorescent cytoprint assay in gynecological malignancies and breast cancer. Methodology and results.

Blackman KE, Fingert HJ, Fuller AF, Meitner PA.

Contrib Gynecol Obstet. 1994;19:53-63. Review. No abstract available.

PMID:
7995053
10.

Incapacitating autonomic neuropathy precipitated by taxol.

Jerian SM, Sarosy GA, Link CJ Jr, Fingert HJ, Reed E, Kohn EC.

Gynecol Oncol. 1993 Nov;51(2):277-80.

PMID:
7903950
11.
12.

Predictive value of the fluorescent cytoprint assay (FCA): a retrospective correlation study of in vitro chemosensitivity and individual responses to chemotherapy.

Leone LA, Meitner PA, Myers TJ, Grace WR, Gajewski WH, Fingert HJ, Rotman B.

Cancer Invest. 1991;9(5):491-503.

PMID:
1933482
13.

Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up.

Thor AD, Schwartz LH, Koerner FC, Edgerton SM, Skates SJ, Yin S, McKenzie SJ, Panicali DL, Marks PJ, Fingert HJ, et al.

Cancer Res. 1989 Dec 15;49(24 Pt 1):7147-52.

14.

Implantation of human meningiomas into the subrenal capsule of the nude mouse. A model for studies of tumor growth.

Medhkour A, Van Roey M, Sobel RA, Fingert HJ, Lee J, Martuza RL.

J Neurosurg. 1989 Oct;71(4):545-50.

PMID:
2477514
15.

In vivo and in vitro enhanced antitumor effects by pentoxifylline in human cancer cells treated with thiotepa.

Fingert HJ, Pu AT, Chen ZY, Googe PB, Alley MC, Pardee AB.

Cancer Res. 1988 Aug 1;48(15):4375-81.

16.

Rapid growth of human cancer cells in a mouse model with fibrin clot subrenal capsule assay.

Fingert HJ, Chen Z, Mizrahi N, Gajewski WH, Bamberg MP, Kradin RL.

Cancer Res. 1987 Jul 15;47(14):3824-9.

17.
18.
19.

Enhanced lethality by methylxanthines in human bladder cancer cells treated with thiotepa.

Fingert HJ, Kindy RL, Pardee AB.

J Urol. 1984 Sep;132(3):609-13.

PMID:
6433047
20.

Megadose chemotherapy with bone marrow rescue.

Fingert HJ, Hochberg FH.

Prog Exp Tumor Res. 1984;28:67-78. No abstract available.

PMID:
6385130

Supplemental Content

Loading ...
Support Center